Alyce Adams

Alyce S Adams, PhD, Stanford Medicine Innovation Professor; Professor, Department of Epidemiology and Population Health; Professor, Department of Medicine (Patient Centered Outcomes Research) 

Research Description: Alyce Adams is a health services and policy researcher with more than 20 years of experience studying modifiable determinants of health care disparities in diabetes and other chronic conditions. Focusing on racial and socioeconomic disparities in chronic disease treatment outcomes, Dr. Adams' interdisciplinary, collaborative research seeks to evaluate the impact of changes in drug coverage policy on access to essential medications, understand the drivers of disparities in treatment adherence among insured populations, and test strategies for maximizing the benefits of treatment outcomes while minimizing harms through informed decision-making.

She is the MPI and Program Director of Diabetes Research for Equity through Advanced Multilevel Science Center for Diabetes Translational Research (DREAMS-CDTR). This center is a collaborative partnership between Stanford, Kaiser Permanente Northern California’s Division of Research (KPNCDOR) and the University of California at San Francisco (UCSF), Merced and Davis to reduce diabetes disparities and improve health equity in northern California. The leadership team will be joined by 16 core faculty members, including Dr. Abby King (SDRC) and an interdisciplinary team of investigators across diverse health system, educational, and research settings to promote the translation of scientific discoveries from bedside to practice and the community to improve diabetes prevention and treatment, and promote health equity. She joined the SDRC Executive Committee to help synergize the activities of the two NIDDK funded diabetes centers at Stanford.

Selected relevant publications (Stanford DRC Members in BOLD):

  1. Kreif N, Sofrygin O, Schmittdiel JA, Adams AS, Grant RW, Zhu Z, van der Laan MJ, Neugebauer R. Exploiting Nonsystematic Covariate Monitoring to Broaden the Scope of Evidence About the Causal Effects of Adaptive Treatment Strategies. Biometrics. 2020 Apr. doi: 10.1111/biom.13271. PMID: 32297311.

  2. Banerjee S, Kim E, Parker MM, Gilliam LK, Dlott R, Adams A. Clinical Response to Real-Time Patient-Reported Diabetic Peripheral Neuropathy Symptoms. Perm J. 2019;23:18-180. doi: 10.7812/TPP/18-180. PMID: 31050645; PMCID: PMC6499113.

  3. Gilsanz P, Schnaider Beeri M, Karter AJ, Quesenberry CP Jr, Adams AS, Whitmer RA. Depression in type 1 diabetes and risk of dementia. Aging Ment Health. 2019 Jul;23(7):880-886. doi: 10.1080/13607863.2018.1455167. PMID: 29634288; PMCID: PMC6179940.

  4. Karter AJ, Parker MM, Solomon MD, Lyles CR, Adams AS, Moffet HH, Reed ME. Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE). Health Serv Res. 2018 Apr;53(2):1227-1247. doi: 10.1111/1475-6773.12700. PMID: 28474736; PMCID: PMC5867086.